Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

INTRODUCTION: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. METHODS: Subjects were aged ≥50 years with...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimers Dement (N Y)
Main Authors: Landen, Jaren W., Andreasen, Niels, Cronenberger, Carol L., Schwartz, Pamela F., Börjesson-Hanson, Anne, Östlund, Henrik, Sattler, Catherine A., Binneman, Brendon, Bednar, Martin M.
Format: Artigo
Language:Inglês
Published: Elsevier 2017
Subjects:
Featured Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651442/
https://ncbi.nlm.nih.gov/pubmed/29067345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2017.05.003
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items